Chronic Low Dosing of Phosphodiesterase Type 5 Inhibitor for Erectile Dysfunction
성현환, 이성원,
소속 상세정보
성현환 ( Sung Hyun-Hwan )
Sungkyunkwan University School of Medicine Samsung Medical Center Department of Urology
이성원 ( Lee Sung-Won )
Sungkyunkwan University School of Medicine Samsung Medical Center Department of Urology
KMID : 0358320120530060377
Abstract
Oral phosphodiesterase type 5 (PDE5) inhibitors have provided non-invasive, effective, and well-tolerated treatments for patients with erectile dysfunction (ED). However, many patients with ED are unresponsive to ’on-demand’ PDE5 inhibitors. In addition, the lack of spontaneity and naturalness of the on-demand regimen could be a reason for decreased compliance with PDE5 inhibitors. Recently, tadalafil and udenafil were approved for low-dose daily administration for the treatment of ED. Since the introduction of the concept of daily administration of PDE5 inhibitors, several reports have supported the potential benefits of this therapy for disease modification, improvement of the treatment response in difficult-to-treat populations, spontaneity, and safety, although further research is needed to better address these hypotheses. In this article, we reviewed the daily administration of PDE5 inhibitors in terms of pharmacokinetics, safety, efficacy, and distinct features.
키워드
Chronic; Erectile dysfunction; Phosphodiesterase 5 inhibitors
원문 및 링크아웃 정보
등재저널 정보